ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) Director Rekha Hemrajani acquired 30,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the purchase, the director now owns 33,000 shares of the company's stock, valued at approximately $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
ALX Oncology Stock Performance
ALXO opened at $1.56 on Thursday. The firm has a market cap of $82.27 million, a PE ratio of -0.52 and a beta of 1.04. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $1.52 and a 200-day simple moving average of $4.17. ALX Oncology Holdings Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $17.83.
Institutional Investors Weigh In On ALX Oncology
Several large investors have recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co acquired a new stake in shares of ALX Oncology in the first quarter worth $27,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock worth $39,000 after buying an additional 5,200 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of ALX Oncology during the second quarter worth $63,000. AQR Capital Management LLC raised its holdings in shares of ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock worth $109,000 after acquiring an additional 6,080 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of ALX Oncology by 413.8% during the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company's stock worth $254,000 after acquiring an additional 18,360 shares in the last quarter. 97.97% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research | Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks.
Today, it’s probably the most popular stock in the world.
I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.
Several equities research analysts have commented on ALXO shares. HC Wainwright reiterated a "buy" rating and issued a $25.00 price target on shares of ALX Oncology in a research report on Tuesday, August 13th. UBS Group reduced their target price on shares of ALX Oncology from $25.00 to $4.00 and set a "buy" rating for the company in a report on Friday, August 16th. Stifel Nicolaus reaffirmed a "hold" rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.50.
View Our Latest Analysis on ALXO
ALX Oncology Company Profile
(
Get Free Report)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
